A Galleria mellonella infection model reveals double and triple antibiotic combination therapies with enhanced efficacy versus a multidrug-resistant strain of Pseudomonas aeruginosa

Journal of Medical Microbiology

Volumn 63, Issue PART 7, 2014, Pages 945-955

  Krezdorn, Jessica ^a   Adams, Sophie ^a   Coote, Peter J ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; COLISTIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; GALLERIA MELLONELLA; HEMOLYMPH; IN VITRO STUDY; IN VIVO STUDY; LARVA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SINGLE DRUG DOSE;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; LARVA; MICROBIAL SENSITIVITY TESTS; MOTHS; PSEUDOMONAS AERUGINOSA;

EID: 84903142947     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.074245-0     Document Type: Article

References (23)

1. Al-Hasan, M. N., Wilson, J. W., Lahr, B. D., Thomsen, K. M., Eckel-Passow, J. E., Vetter, E. A., Tleyjeh, I. M. & Baddour, L. M. (2009). blactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by Gram-negative bacilli. Antimicrob Agents Chemother 53, 1386-1394.
2. Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S. & Carmeli, Y. (2006). Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50, 43-48.
3. Bodey, G. P., Jadeja, L. & Elting, L. (1985). Pseudomonas Bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 145, 1621-1629.
4. Bowers, D. R., Liew, Y.-X., Lye, D. C., Kwa, A. L., Hsu, L.-Y. & Tam, V. H. (2013). Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 57, 1270-1274.
5. Chandrasekar, P. H., Crane, L. R. & Bailey, E. J. (1987). Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J Antimicrob Chemother 19, 321-329.
6. Dales, L., Ferris, W., Vandemheen, K. & Aaron, S. D. (2009). Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 28, 1275-1279.
7. He, W., Kaniga, K., Lynch, A. S., Flamm, R. K. & Davies, T. A. (2012). In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method. Diagn Microbiol Infect Dis 74, 417-419.
8. Hilf, M., Yu, V. L., Sharp, J., Zuravleff, J. J., Korvick, J. A. & Muder, R. R. (1989). Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 87, 540-546.
9. Hill, L., Veli, N. & Coote, P. J. (2013). Evaluation of Galleria mellonella larvae for measuring the efficacy and pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection. Int J Antimicrob Agents 43, 254-261.
10. Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scand J Stat 6, 65-70.
11. Lister, P. D., Wolter, D. J. & Hanson, N. D. (2009). Antibacterialresistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22, 582-610.
12. Livermore, D. M. (2002). Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34, 634-640.
13. Micek, S. T., Lloyd, A. E., Ritchie, D. J., Reichley, R. M., Fraser, V. J. & Kollef, M. H. (2005). Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49, 1306-1311.
14. Oie, S., Uematsu, T., Sawa, A., Mizuno, H., Tomita, M., Ishida, S., Okano, Y. & Kamiya, A. (2003). In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 52, 911-914.
15. Samonis, G., Maraki, S., Karageorgopoulos, D. E., Vouloumanou, E. K. & Falagas, M. E. (2012). Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrugresistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 31, 695-701.
16. Scribner, R. K., Marks, M. I., Weber, A. H., Tarpay, M. M. & Welch, D. F. (1982). Activities of various b-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother 21, 939-943.
17. Spencer, R. C. (1996). Predominant pathogens found in the European prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis 15, 281-285.
18. Tamma, P. D., Cosgrove, S. E. & Maragakis, L. L. (2012). Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25, 450-470.
19. Vardakas, K. Z., Tansarli, G. S., Bliziotis, I. A. & Falagas, M. E. (2013). b-Lactam plus aminoglycoside or fluoroquinolone combination versus b-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents 41, 301-310.
20. Vidaillac, C., Benichou, L. & Duval, R. E. (2012). In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 56, 4856-4861.
21. White, R. L., Burgess, D. S., Manduru, M. & Bosso, J. A. (1996). Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 40, 1914-1918.
22. Winston, D. J., Ho, W. G., Bruckner, D. A. & Champlin, R. E. (1991). Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 115, 849-859.
23. Woodford, N., Zhang, J., Kaufmann, M. E., Yarde, S., Tomas, M. M., Faris, C., Vardhan, M. S., Dawson, S., Cotterill, S. L. & Livermore, D. M. (2008). Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum b-lactamases in the United Kingdom. J Antimicrob Chemother 62, 1265-1268.